FDA is requiring that all
postmarketing safety reports for human drugs and biological
products be submitted in electronic format. Requiring submission of
these reports in electronic format will expedite access to safety
information and facilitate international harmonization and exchange
of this information. This, in turn, will lead to more efficient
reviews of safety data and enhance our ability to rapidly
disseminate safety information to health care providers, consumers,
applicants, sponsors, and other regulatory authorities in support
of FDA's public health mission. In addition, the Agency will
recognize a significant cost savings by converting the safety
reporting system from a paper submission process to an all
electronic system that would increase the accuracy of information
and reduce the need for manual data entry. The final rule will
expedite the identification of emerging safety problems, improve
the speed and efficiency of industry and agency operations, and
further the international harmonization of safety
reporting.
The information collection
request revises the currently approved collection under OMB Control
No. 0910-0770. The "Stage of Rulemaking" was mistakenly entered in
ROCIS as a Proposed Rule, and should have been entered as a Final
Rule. There are no other changes to this information collection
request
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.